drugset / Trial / NCT02172963

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

NCT02172963

Phase 1/2 Completed 12 enrolled Karolinska Institutet
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.

Timeline

Start
2011-11
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Decidual Stromal Cells Cell therapy 1e+06 cells/kg Intravenous
Subject Decidual Stromal Cells Cell therapy 2e+06 cells/kg Intravenous

Indications